Remedium Capital Partners, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0002104501

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 Q2 2026 Q1 2026 Q4 2025

Q3 2026 · 6 positions · Total reported value $273.59M · Top-10 concentration 100.0% · Updated 2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

Turnover: 57.1% · 1 new · 2 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Remedium Capital Partners, LLC disclosed 6 equity positions with a combined reported value of $273.59M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were SYRE ($103.33M), ORKA ($79.47M), DMRA ($43.53M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+17.2pp) and away from Other (-17.2pp).

Versus the prior quarter, Remedium Capital Partners, LLC opened 1 new positions, trimmed 2 and fully exited 1, a turnover rate of 57.1% of positions. The portfolio's overlap with the prior quarter was 71% of names.

The largest new positions opened in Q3 2026 were ANIX ($16.59M).

Of the 1 positions fully exited versus the prior quarter, the largest were APGE ($77.87M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ANIX KORSANA BIOSCIENCES INC · $16.59M

Fully Exited (vs previous quarter)

  • APGE APOGEE THERAPEUTICS INC · prev qtr: $77.87M

Insider Transactions (Form 4)

Latest Remedium Capital Partners, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Remedium Capital Partners, LLC, based in West Palm Beach, FL, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 6 positions worth $451.63M in total. HoldingsHub carries 3 quarters of its filings (Q4 2025–Q2 2026).

Firm Snapshot

  • Headquarters: WEST PALM BEACH, FL, United States
  • SEC registration: 801-135411 (status: Approved), registered 2026-05-26
  • Regulatory AUM (Form ADV): $319.00M as of 2026-08-20
  • Website: remediumcp.com

Portfolio Structure

  • 6 positions · $451.63M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: ORKA (ORUKA THERAPEUTICS INC) at 33.0%
  • Average position size: $75.27M

Sector Tilt

  • Health Care 82.8%
  • (classified holdings cover 83% of value)

Quarterly Activity

  • Q2 2026: 2 added
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund reduced exposure to two top holdings (SYRE, ORKA) while adding a new position (ANIX) and increasing weight in others (JBIO), suggesting a cautious but selective approach to biotech/healthcare, possibly trimming overexposed names and diversifying. 2. Key moves: - Reduced: SYRE (shares -20.7%, wt +9pp), ORKA (shares -39.1%, wt -3.9pp). - Added: JBIO (shares +14.6%, wt +1.5pp). - New: ANIX (6.07% weight). 3. Portfolio structure: Active, concentrated (6 positions), heavily biased toward Health Care (biotech/therapeutics), with moderate risk appetite (high conviction in few names). 4. Per-holding one-liner: - SYRE: SPYRE Therapeutics (biopharma, unverified). - ORKA: ORUKA Therapeutics (biopharma, unverified). - DMRA: DAMORA Therapeutics (biopharma, unverified). - JBIO: JADE Biosciences (biopharma, unverified). - ANIX: ANIXA Biosciences (immunology, unverified). - CBIO: Crescent Biopharma (oncology, unverified). 5. Style summary: Biotech-focused fund actively trimming overweights while selectively adding new positions, reflecting a cautious yet opportunistic view on healthcare innovation.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-15 02:37

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.16M $103.33M 37.77%
37.77%
Reduce
2 954.15K $79.47M 29.05%
29.05%
Reduce
3 2.05M $43.53M 15.91%
15.91%
Hold
4 1.81M $25.40M 9.28%
9.28%
Add
5 518.50K $16.59M 6.07%
6.07%
New
6 361.25K $5.27M 1.93%
1.93%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 83% R 83% F1 83% (modelled on 2026-Q2; 5/10 hit)

Historical Backtest (2 quarters)

Avg precision 92% · recall 92% · F1 92% · avg rank error 1.4 · Top-10 turnover 6%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2026-Q2 100% 100% 100% ORKA · SYRE · DMRA · APGE · JBIO · CBIO ORKA · SYRE · APGE · DMRA · JBIO · CBIO
2026-Q3 ★ 83% 83% 83% ORKA · SYRE · APGE · DMRA · JBIO · CBIO SYRE · ORKA · DMRA · JBIO · ANIX · CBIO

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Remedium Capital Partners, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Remedium Capital Partners, LLC reported 6 equity positions worth $273.59M in aggregate; its largest disclosed positions were SYRE ($103.33M), ORKA ($79.47M), DMRA ($43.53M).

How large is Remedium Capital Partners, LLC's portfolio?

Remedium Capital Partners, LLC reported $273.59M of long equity holdings across 6 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.

What is Remedium Capital Partners, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/remedium-capital-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →